SCHEMBL5405791

SCHEMBL5405791

Cc1cccc(NC(=O)c2ccc3[nH]ncc3c2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.65
MAOA P21397 1/20 0.64
NPC1 O15118 4/20 0.63
RAB9A P51151 4/20 0.63
ROCK2 O75116 2/20 0.63
MAP4K4 O95819 2/20 0.63
RPS6KB1 P23443 2/20 0.63
CLK2 P49760 2/20 0.63
ROCK1 Q13464 2/20 0.63
DYRK1A Q13627 2/20 0.63
CLK4 Q9HAZ1 2/20 0.63
DYRK3 O43781 1/20 0.63
CSNK2A1 P68400 1/20 0.63
MKNK2 Q9HBH9 1/20 0.63
JAK2 O60674 1/20 0.63
PRKD3 O94806 1/20 0.60
PRKG1 Q13976 1/20 0.60
PRKD2 Q9BZL6 1/20 0.60
SGK2 Q9HBY8 1/20 0.60
STK17A Q9UEE5 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5415932 0.86 MAOB (0.69) MAOBMAOANPC1RAB9AROCK2
SCHEMBL5182382 0.85 NPC1 (0.75) MAOBNPC1RAB9AROCK2MAP4K4
SCHEMBL5415117 0.85 MAOB (0.80) MAOBMAOANPC1RAB9AROCK2
SCHEMBL5415113 0.85 NPC1 (0.82) MAOBMAOANPC1RAB9AROCK2
SCHEMBL5069515 0.84 MEN1 (0.56) MAOBMAOANPC1RAB9A
SCHEMBL5413244 0.84 NPC1 (0.83) MAOBMAOANPC1RAB9A
SCHEMBL5401343 0.84 NPC1 (0.65) MAOBNPC1RAB9AROCK2MAP4K4
SCHEMBL9959880 0.81 MAOB (0.63) MAOBMAOANPC1RAB9AROCK2
SCHEMBL5381378 0.81 NPC1 (0.76) MAOBNPC1RAB9AROCK2MAP4K4
SCHEMBL5412469 0.81 ROCK2 (0.64) MAOBNPC1RAB9AROCK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 US disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA MAOB 2025/4885MAOA 2003/4885NPC1 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.